US FDA approves ImmunityBio’s bladder cancer therapy
The U.S. health regulator approved on Monday ImmunityBio’s combination therapy to treat a type of bladder cancer, marking an end to the company’s efforts to bring its therapy to the market.
The U.S. health regulator approved on Monday ImmunityBio’s combination therapy to treat a type of bladder cancer, marking an end to the company’s efforts to bring its therapy to the market.
Successful surgery for infective endocarditis is not enough to ensure good long-term outcomes in patients with opioid use disorder, study makes clear New and different…
This pooled cohort study clarifies the association between cumulative mean systolic blood pressure and incident stroke types and explores whether race and ethnicity modify these…
On May 8, join us for a conversation with practicing neurologists about overcoming current hurdles involved in diagnosing, treating, and monitoring patients in a new…
Hospitals’ operating margins and patient volumes dropped slightly in March. While hospitals were doing relatively well financially during the first quarter of the year, this…
With self-harm on the rise in teens, it’s important for the adults who love them to know about this sign of psychological distress. An expert…
Moore et al. studied antibody and cellular responses to COVID-19 vaccines before and after dose 3. Antibody responses waned, but T cell responses were well maintained. T cells…
Learn about CDC’s “boots-on-the-ground” disease detectives: who they are, how they protect the public’s health, and how to become one.
Like all relationships, our relationship with our customers is built on trust. You trust us with handling and securing the life blood of your company…